The Unseen Shift: Why Big Pharma is Turning to China for Blockbuster Drugs
The American pharmaceutical industry is increasingly collaborating with Chinese firms, with 30% of Big Pharma deals in 2024 involving Chinese companies. Chinese pharmaceutical firms offer advanced development capabilities, efficient molecule creation, and competitive costs. Licensing deals are crucial, allowing U.S. companies access
